PB1904: TRIAL IN PROGRESS: A PHASE III STUDY OF ASCIMINIB VS AN INVESTIGATOR-SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
T. Hughes,
J. Cortes,
N. Takahashi,
R. Larson,
G. Issa,
F. Bombaci,
N. Ramscar,
S. Kapoor,
S. Ifrah,
A. Hochhaus
Affiliations
T. Hughes
1 SA Pathology and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia
J. Cortes
2 Georgia Cancer Center, Augusta, United States of America
N. Takahashi
3 Akita University, Akita City, Japan
R. Larson
4 The University of Chicago, Chicago
G. Issa
5 The University of Texas MD Anderson Cancer Center, Houston, United States of America
F. Bombaci
6 CML Advocates Network, Turnin, Italy
N. Ramscar
7 Novartis Pharma AG, Basel, Switzerland
S. Kapoor
8 Novartis Pharmaceuticals Corporation, East Hanover, United States of America
